164 related articles for article (PubMed ID: 38845393)
1. Evinacumab: Mechanism of action, clinical, and translational science.
Dingman R; Bihorel S; Gusarova V; Mendell J; Pordy R
Clin Transl Sci; 2024 Jun; 17(6):e13836. PubMed ID: 38845393
[TBL] [Abstract][Full Text] [Related]
2. Evinacumab for Homozygous Familial Hypercholesterolemia.
Raal FJ; Rosenson RS; Reeskamp LF; Hovingh GK; Kastelein JJP; Rubba P; Ali S; Banerjee P; Chan KC; Gipe DA; Khilla N; Pordy R; Weinreich DM; Yancopoulos GD; Zhang Y; Gaudet D;
N Engl J Med; 2020 Aug; 383(8):711-720. PubMed ID: 32813947
[TBL] [Abstract][Full Text] [Related]
3. Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia?
Doggrell SA
Expert Opin Biol Ther; 2021 Mar; 21(3):299-302. PubMed ID: 33295805
[No Abstract] [Full Text] [Related]
4. Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia.
Béliard S; Saheb S; Litzler-Renault S; Vimont A; Valero R; Bruckert É; Farnier M; Gallo A
Arterioscler Thromb Vasc Biol; 2024 Jun; 44(6):1447-1454. PubMed ID: 38695169
[TBL] [Abstract][Full Text] [Related]
5. Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia.
Pirillo A; Catapano AL
Expert Opin Biol Ther; 2022 Jul; 22(7):813-820. PubMed ID: 35698895
[TBL] [Abstract][Full Text] [Related]
6. Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia.
White RT; Sankey KH; Nawarskas JJ
Cardiol Rev; 2024 Mar-Apr 01; 32(2):180-185. PubMed ID: 37071085
[TBL] [Abstract][Full Text] [Related]
7. Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
Wiegman A; Greber-Platzer S; Ali S; Reijman MD; Brinton EA; Charng MJ; Srinivasan S; Baker-Smith C; Baum S; Brothers JA; Hartz J; Moriarty PM; Mendell J; Bihorel S; Banerjee P; George RT; Hirshberg B; Pordy R
Circulation; 2024 Jan; 149(5):343-353. PubMed ID: 37860863
[TBL] [Abstract][Full Text] [Related]
8. Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity.
Banerjee P; Chan KC; Tarabocchia M; Benito-Vicente A; Alves AC; Uribe KB; Bourbon M; Skiba PJ; Pordy R; Gipe DA; Gaudet D; Martin C
Arterioscler Thromb Vasc Biol; 2019 Nov; 39(11):2248-2260. PubMed ID: 31578082
[TBL] [Abstract][Full Text] [Related]
9. Lessons learned from the evinacumab trials in the treatment of homozygous familial hypercholesterolemia.
Khoury E; Croteau L; Lauzière A; Gaudet D
Future Cardiol; 2022 Jun; 18(6):507-518. PubMed ID: 35469449
[TBL] [Abstract][Full Text] [Related]
10. Homozygous familial hypercholesterolemia: what treatments are on the horizon?
Bajaj A; Cuchel M
Curr Opin Lipidol; 2020 Jun; 31(3):119-124. PubMed ID: 32332430
[TBL] [Abstract][Full Text] [Related]
11. Advancements in the Treatment of Homozygous Familial Hypercholesterolemia.
Bajaj A; Cuchel M
J Atheroscler Thromb; 2022 Aug; 29(8):1125-1135. PubMed ID: 35466160
[TBL] [Abstract][Full Text] [Related]
12. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab.
Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G
Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors.
Pirillo A; Catapano AL; Norata GD
Curr Atheroscler Rep; 2021 Oct; 23(12):79. PubMed ID: 34698927
[TBL] [Abstract][Full Text] [Related]
14. Novel therapies for familial hypercholesterolemia.
Mohamed F; Seedat F; Raal FJ
Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):188-195. PubMed ID: 33278127
[TBL] [Abstract][Full Text] [Related]
15. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
Raal FJ; Hegele RA; Ruzza A; López JAG; Bhatia AK; Wu J; Wang H; Gaudet D; Wiegman A; Wang J; Santos RD
Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1156-1164. PubMed ID: 38545781
[TBL] [Abstract][Full Text] [Related]
16. Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry.
D'Erasmo L; Bini S; Casula M; Gazzotti M; Bertolini S; Calandra S; Tarugi P; Averna M; Iannuzzo G; Fortunato G; Catapano AL; Arca M;
Eur J Prev Cardiol; 2024 Jun; 31(8):1038-1047. PubMed ID: 38374534
[TBL] [Abstract][Full Text] [Related]
17. Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia.
Kosmas CE; Bousvarou MD; Sourlas A; Papakonstantinou EJ; Peña Genao E; Echavarria Uceta R; Guzman E
Clin Pharmacol; 2022; 14():49-59. PubMed ID: 35873366
[TBL] [Abstract][Full Text] [Related]
18. Evinacumab for treatment of familial hypercholesterolemia.
Warden BA; Duell PB
Expert Rev Cardiovasc Ther; 2021 Aug; 19(8):739-751. PubMed ID: 34253139
[No Abstract] [Full Text] [Related]
19. Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia.
Ito MK; Watts GF
Drugs; 2015 Oct; 75(15):1715-24. PubMed ID: 26370207
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1).
Gaudet D; Durst R; Lepor N; Bakker-Arkema R; Bisgaier C; Masson L; Golden L; Kastelein JJ; Hegele RA; Stein E
Am J Cardiol; 2019 Dec; 124(12):1876-1880. PubMed ID: 31685212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]